Overview
COYA market data
Price History
COYA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.27 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.63 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -266.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.71 – $7.75 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $108.8M · P/B 2.82 · P/S 13.71.
Company News
Coya Therapeutics Q2 EPS $(0.28) Beats $(0.34) Estimate, Sales $243.745K Beat $100.000K EstimateBenzinga · Aug 11, 2026, 12:11 PM
8-K filing — Coya Therapeutics, Inc. (COYA)SEC EDGAR · Aug 11, 2026, 12:03 PM
8-K/A filing — Coya Therapeutics, Inc. (COYA)SEC EDGAR · Aug 7, 2026, 9:00 PM
Coya Therapeutics To Present Overview Of Ongoing ALSTARS Trial At European Network To Cure ALS June 24-26Benzinga · Jun 18, 2026, 12:15 PM
Coya Therapeutics Initiates Blinded Extension Phase Of Its ALSTARS Trial; Patients Who Complete The 24-Week Placebo-Controlled, Double-Blind Phase Enter The Blinded Extension Phase Of The StudyBenzinga · Jun 8, 2026, 12:15 PM
This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga · Jun 5, 2026, 12:55 PM